SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending due to its notable resilience and outperformance against Bitcoin, fueled by anticipation for the upcoming CashVM upgrade in May 2026 which aims to significantly enhance its programmability. This is sparking renewed discussion about BCH's potential as the 'true Bitcoin' amidst broader optimism for an Altcoin Season and the Clarity Act.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL) is seeing heightened community discussion driven by its new listing on a major Chinese exchange and the integration of Alchemy Pay's fiat on-ramp. Investors are sharply divided, with some anticipating a significant rebound for the stablecoin utility token, while others vehemently label it a pump-and-dump.

ShapeShift is a decentralized, multichain cryptocurrency platform that empowers users to swap, track, buy, and earn with over 30,000 assets across the top blockchains such as Bitcoin, Ethereum, Dogecoin, Cosmos, and more. The platform emphasizes financial sovereignty and self-custody, providing an open-source environment where users can engage with the most popular crypto tools and services to trade, earn, and hodl their digital assets. FOX token holders can submit and vote on proposals, helping to shape the future of ShapeShift.

ShapeShift FOX Token

FOX CRYPTO is gaining attention as investors believe the ShapeShift FOX Token is significantly undervalued with a low market cap compared to its DeFi competitors. The community is actively discussing its technical setup, anticipating an imminent breakout from a prolonged downtrend that could lead to a substantial rally as alt season approaches.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is a focus of community discussion due to its accelerated commercialization plans and anticipated Phase 3 data for its COMP360 psilocybin therapy, expected in Q1 2026. Investors are weighing its potential as a first-to-market, durable treatment for depression against ongoing debates regarding its treatment duration and competition from emerging shorter-acting alternatives.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as its Meta partnership for AI data center power and ongoing discussions around small modular reactor technology, government support, and regulatory approvals drive conversation. The community is actively weighing its potential as a vertically integrated energy solution for the AI boom against its pre-revenue status and high-risk speculative nature.

LayerZero

LayerZero ($ZRO) is trending as the community highlights its crucial role in enabling the multi-chain functionality of the $CAW meme coin, which is noted as the first Cronos project to utilize LayerZero's OFT protocol and its bridge-burn mechanism. Enthusiasts are actively discussing LayerZero's integral technology for cross-chain interoperability and potential ecosystem expansion, such as the Stargate acquisition, driving bullish sentiment.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid intense speculation of an imminent acquisition by major tech players, fueled by its unique n53 spectrum and pivotal role in Apple's direct-to-device strategy. The community eagerly awaits key FCC decisions, believing these will unlock significant value for its expansive private 5G and IoT solutions, including new applications for drones.

Bridgford Foods Corp. engages in the manufacture, market, and distribution of frozen and snack food products. It operates through the Frozen Food Products and Snack Food Products segments. The Frozen Food Products segment manufactures and distributes food products, including biscuits, bread dough items, roll dough items, and sandwiches. The Snack Food Products segment distributes both products manufactured by the company and third parties. The company was founded by Hugh H. Bridgford in February 1932 and is headquartered in Dallas, TX.

Bridgford Foods Corp.

Bridgford Foods Corporation

Bridgford Foods is trending as the community speculates on significant margin improvements from recent initiatives to lower beef prices through increased imports, alongside the broader market rotation into defensive food stocks. Investors are also noting the company's aggressive push into private-label offerings with major retailers, viewing BRID as a deeply undervalued play with substantial hidden asset value.

BlockDAG

BlockDAG (BDAG) is trending amidst intense community frustration over persistent launch delays and widespread reports of technical issues preventing investors from claiming their presale tokens. Accusations of a scam or "rug pull" are prevalent as many users report their purchased coins disappearing and express discontent with the project's transparency.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is a trending topic due to community backlash over its vague 2026 roadmap and persistent issues with exchange listings, KYC, and locked balances; however, a loyal cohort maintains belief in its long-term vision as a foundational currency, advocating for continued mining.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Palladyne expects to complete the deliverables by the third quarter of 2026.</li><li>The contract projected to generate nearly $1 million in revenue for fiscal 2026.</li><li>The win positions Palladyne for a bigger involvement in future long-duration missile programs, the company said.&nbsp;</li></ul>Shares of Palladyne AI Corp. (PDYN) jumped more than 10% in pre-market trading on Tuesday after the company signed an agreement with a major U.S. defense prime contractor to supply a mission-critical subsystem supporting missile propulsion for an existing U.S. missile program.<a href="https://stocktwits.com/symbol/PDYN">PDYN shares</a> jumped 17% after the opening bell.Palladyne expects to complete the deliverables by the third quarter of 2026, with the contract projected to generate nearly $1 million in revenue for the year. The win also positions Palladyne for a bigger involvement in future long-duration missile programs, the company said.“Beyond the initial contract, we believe we are well positioned for growing annual revenues from this program,” said Ben Wolff, CEO of Palladyne AI.<h2 class="st-heading-2">Palladyne’s Latest Contracts</h2>This comes on the back of two recent contracts. Last month, Palladyne AI was awarded a contract by the Air Force Research Laboratory (AFRL) for project HANGTIME to enable autonomous systems to operate as a coordinated unit. The project will use Palladyne’s SwarmOS to connect drones, ships, satellites, and ground systems, allowing them to share intelligence, adapt in real time, and execute synchronized missions across domains.In a separate development, Palladyne’s subsidiary GuideTech secured a contract with Portal Space Systems to support next-generation maneuverable spacecraft. GuideTech will provide navigation, guidance, spacecraft modeling, embedded software, and avionics expertise, expanding Palladyne’s footprint into the space sector.Palladyne also released its FY2026 forecast, expecting revenue between $24 million and $27 million, representing significant growth driven by new contracts, rising customer demand, and the integration of recently acquired businesses.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/PDYN_jpg_f922841080.webp" alt="PDYN.jpg">One user expects the stock to climb to $10. It is currently at $7.91.<stembedurl>https://stocktwits.com/Lando4/message/643785073</stembedurl>The stock has seen heavy buying interest so far in 2026, surging 84%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Palladyne AI Corp. logo is seen displayed on a smartphone screen. 

Why Did PDYN Stock Pop Over 10% In Pre-Market Today?

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

Palladyne AI Stock Is Surging After Landing A Pentagon-Linked Missile Contract 

Equity

<ul class="summary-bullets"><li>The drug is now expected to be available in the U.S. in the second half of January 2026.</li><li>The prescribing information for the drug includes a warning for the risk of heart failure due to systolic dysfunction.</li><li>Myqorzo is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) because of the risk of heart failure.</li></ul> Shares of Cytokinetics, Incorporated (CYTK) soared as much as 7% after hours before paring back gains on Friday after the company said that its drug Myqorzo for the treatment of adults with thickened heart muscle has been approved by the U.S. Food and Drug Administration.The agency approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy and aimed at improving functional capacity and symptoms. Symptomatic obstructive hypertrophic cardiomyopathy means the individual has a thickened heart muscle that blocks blood flow out of the heart, causing symptoms like shortness of breath, chest pain (especially with exertion), palpitations, dizziness, fatigue, and fainting.The approval marks the company’s first by the FDA. “I’m pleased that the approved label and REMS reflect the distinct characteristics of Myqorzo including a straightforward, flexible dosing regimen, no requirement for drug-drug interaction monitoring and a predictable safety profile,” CEO Robert I Blum <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/19/3208724/35409/en/Cytokinetics-Announces-FDA-Approval-of-MYQORZO-aficamten-for-the-Treatment-of-Adults-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Improve-Functional-Capacity-and-Sym.html">said</a>.The drug is now expected to be available in the U.S. in the second half of January 2026.<h2 class="st-heading-2">Risks Associated</h2>The prescribing information for the drug includes a warning for the risk of heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with Myqorzo to monitor for systolic dysfunction, the company said. The initiation of the drug is not recommended for patients with low Left Ventricular Ejection Fraction (LVEF). LVEF refers to the percentage of blood pumped out of the heart's main pumping chamber, the left ventricle, with each heartbeat.Myqorzo is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) because of the risk of heart failure.FDA approved the drug on the basis of results from a late-stage trial in which Myqorzo improved exercise capacity and reduced symptoms. The drug was also well tolerated in the study with no instances of worsening heart failure or treatment interruptions. Treatment emergent serious adverse events occurred in 5.6% of patients on the drug and 9.3% of patients on placebo.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CYTK stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user highlighted that the recommended monitoring during the drug’s use is “pretty reasonable.”<stembedurl>https://www.stocktwits.com/kgpittm/message/639758721</stembedurl>Another expressed surprise at the stock trading in the red despite the “great news.”<stembedurl>https://www.stocktwits.com/Kim_Jong_Moon/message/639763223</stembedurl><a href="https://stocktwits.com/symbol/CYTK">CYTK stock</a> has risen 33% this year and by about 34% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/atai-beckley-supernus-jump-as-wall-street-flags-psychedelics-tailwinds-from-trump-marijuana-order/cLe02tNREtb">Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Cytokinetics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious?

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

<ul class="summary-bullets"><li>The analyst said the market may be underestimating the impact of autonomous vehicles on the company’s discounted cash flow.&nbsp;</li><li>Risks also arise from Lyft's U.S. ridesharing market exposure and undiversified offering mix, he added.&nbsp;</li><li>Earlier, Jefferies lowered its price target to $22 from $23 while keeping a ‘Hold’ rating, as per TheFly.</li></ul>Wedbush Equity Research Analyst Scott Devitt downgraded Lyft Inc. (<a href="https://stocktwits.com/symbol/LYFT">LYFT</a>) to ‘Underperform’ from ‘Neutral’ and reduced its price target to $16 from $20, citing risks from the impact of autonomous vehicle disruption.Devitt said that the firm believes the risk comes from Lyft's U.S. ridesharing market exposure and undiversified offering mix, according to TheFly. Wedbush believes the market is misreading the negative terminal value impact that autonomous vehicles may have on the company’s discounted cash flow value.<h2 class="st-heading-2">Autonomous Rides Push</h2>In October, Lyft partnered with Tensor Auto to bring the California-based Robocars onto its platform in 2027. Individual owners can list Tensor’s vehicles on the platform in select markets once approved. The company has reserved hundreds of Robocars across Europe and North America. Lyft is also partnering with Alphabet’s Waymo to launch the latter’s fully autonomous ride-hailing service in Nashville in 2026.Lyft’s push into autonomous vehicles comes as rival Uber Technologies (UBER) is amping up its own efforts to expand its global AV fleets. Recently, UBER announced that it will leverage NVIDIA’s AI Architecture to accelerate its robotaxi and autonomous fleet offerings. The ride-hailing company is already offering autonomous robotaxi rides with WeRide (WRD) in Riyadh, though it currently has a vehicle operator.Earlier, Jefferies lowered Lyft’s to $22 from $23 while keeping a ‘Hold’ rating, as per TheFly.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around Lyft remained in the ‘neutral’ territory over the past 24 hours, and message volume stayed at ‘high’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1288/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_19_at_7_23_46_PM_png_c2fe0aa8c6.webp" alt="On Stocktwits, the retail sentiment around Lyft remained in the ‘neutral’ territory over the past 24 hours, and message volume stayed at ‘high’ levels at the time of writing." width="1288" height="156"></figure>LYFT was among the top trending tickers on Stocktwits at the time of writing.Shares of LYFT are up over 46% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Lyft's logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Lyft Draws Investor Attention After Wedbush Downgrades Stock Amid Autonomous Vehicle Risks

Wedbush Equity Research Analyst Scott Devitt reduced the price target on Lyft to $16 from $20. 

<ul class="summary-bullets"><li>According to the company, preliminary analysis of the data showed a 72% reduction in CRBSI and a 70% reduction in secondary hospitalizations.&nbsp;</li><li>The study was based on results from approximately 7,000 patients who received at least one dose of DefenCath in Year 1.</li><li>The latest DefenCath results indicate meaningful risk reduction among some of the most vulnerable patients and significant cost reductions, the company said.</li></ul>CorMedix Inc. (<a href="https://stocktwits.com/symbol/CRMD">CRMD</a>) stated on Thursday that its DefenCath, a catheter lock solution, had fewer catheter-related bloodstream infections (CRBSI) and secondary hospitalizations in adult dialysis patients as shown in its ongoing real-world interim study conducted in conjunction with U.S. Renal Care.The use of DefenCath resulted in a 72% reduction in CRBSI and a 70% reduction in hospitalizations secondary to CRBSI in the preliminary analysis of interim data for approximately 7,000 patients who received at least one dose of DefenCath in Year 1, the company said.Shares of CRMD were up over 2% on Thursday morning.<h2 class="st-heading-2">DefenCath Solutions</h2>CorMedix said that it believes the latest results about DefenCath indicate a meaningful risk reduction among some of the most vulnerable patients. The biopharmaceutical company added that it would also significantly save costs for the healthcare community.Centers for Medicare &amp; Medicaid Services (CMS) spends more than $3 billion per year on costs associated with CRBSI, with the average CRBSI-related hospitalization estimated to cost between $63,000 and $110,000 per incident, approximately, the company said.Joseph Todisco, CEO at CorMedix, said the interim results from the study will be used to support broader adoption of DefenCath and advance long-term reimbursement discussions, including with Medicare Advantage.“Our organization is deeply committed to advancing innovative therapies for our patients, and we are encouraged by the reduction in both serious infections and hospitalizations demonstrated in these preliminary results,” said Geoffrey A. Block, Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around CRMD jumped to ‘bullish’ from ‘bearish’ levels over the past day, and message volume changed to ‘normal’ from ‘low’ levels.<figure class="image"><img style="aspect-ratio:1274/160;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_18_at_9_42_40_PM_png_b7b4e3b880.webp" alt="On Stocktwits, the retail sentiment around CRMD jumped to ‘bullish’ from ‘bearish’ levels over the past day, and message volume changed to ‘normal’ from ‘low’ levels." width="1274" height="160"></figure> Shares of CRMD are up over 44% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is CorMedix Stock Rising Today?

CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.

<ul class="summary-bullets"><li>Insmed subsequently decided to discontinue the program with immediate effect.</li><li>The company also announced that it has acquired a new experimental drug called INS1148.&nbsp;</li><li>The new drug adds to the company’s pipeline, the most advanced of which are in pulmonary and inﬂammatory conditions. &nbsp;</li></ul>Shares of Insmed Incorporated (INSM) slumped nearly 17% in after-hours trading on Wednesday after the company said that its mid-stage stage study of Brensocatib in patients with chronic rhinosinusitis without nasal polyps did not meet its defined goals.While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in the study even at its highest dose of 40 mg, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/insmed-provides-clinical-and-business-update-302645128.html">said.</a> The failed study was conducted across 104 sites globally and enrolled a total of 288 patientsInsmed subsequently decided to discontinue the program with immediate effect. "While we are disappointed in the results, they provided us with a clear answer,” Chief Medical Officer of Insmed Martina Flammer said.<h2 class="st-heading-2">Gearing Forward With New Acquisition</h2>Bridgewater, New Jersey-headquartered Insmed also announced on Wednesday that it has acquired a new experimental drug called INS1148 with potential in addressing respiratory and immunological and inflammatory diseases. The company now plans to advance mid-stage development plans for the drug initially in interstitial lung disease and moderate-to-severe asthma.The drug was developed by privately held pharmaceutical company Opsidio and formerly known as OpSCF.The drug adds to the company’s pipeline, the most advanced of which are in pulmonary and inﬂammatory conditions.<h2 class="st-heading-2">Pipeline And Approvals</h2>Last month, the European Commission approved the company’s Brinsupri for the treatment of a chronic and progressive lung disease non-cystic fibrosis bronchiectasis in patients 12 years of age and older. It is the only approved treatment for the condition in the European Union.Brinsupri was approved by the U.S. Food and Drug Administration for the treatment of the condition in August. Non-cystic fibrosis bronchiectasis is a chronic lung condition where airways become permanently widened and damaged, leading to a vicious cycle of mucus buildup, infection, inflammation, and cough with sputum.<h2 class="st-heading-2">Analyst Optimism Dampened</h2>Cantor Fitzgerald had raised the price target on Insmed to $230 from $216 on Wednesday in anticipation of the trial results. The analyst, who kept an ‘Overweight’ rating on the shares, had termed the study results as the stock’s “next important catalyst” and had said that it sees a "good chance" of Brensocatib showing a benefit in chronic rhinosinusitis without nasal polyps.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around Insmed stayed within the ‘bullish’ territory over the past 24 hours while message volume stayed at 'high' levels.<a href="https://stocktwits.com/symbol/INSM">INSM stock</a> has nearly tripled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/archer-eyes-deploying-air-taxis-in-major-us-cities-amid-short-sellers-no-fly-concerns/cLeOuYiREAG">Archer Eyes Deploying Air Taxis In Major US Cities Backed By Government Push Amid Short Seller’s No-Fly Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit

While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg. 

<ul class="summary-bullets"><li>The retirement comes after the company reported strong performance in its investment banking business for Q3.&nbsp;</li><li>Earlier this month, JPMorgan consumer and community banking chief Marianne Lake said that it expects expenses to climb to about $105 billion in 2026.&nbsp;</li><li>Lake also said that investment banking revenue is expected to be up by the low-single digit percentages in the fourth quarter.</li></ul>JPMorgan Chase &amp; Co’s investment banking (JPM) Chairman Jamie Grant is reportedly set to retire from the firm early next year.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-15/jamie-grant-is-said-to-retire-from-jpmorgan-after-four-decades">reported</a> on Monday, citing people familiar with the matter and a memo, that Grant is slated to leave after 45 years at the lender. According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking.<h2 class="st-heading-2">AI Push, Rising Costs</h2>Earlier this month, JPMorgan consumer and community banking chief Marianne Lake <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-is-pouring-billions-into-tech-to-rewire-the-bank-for-the-ai-age/cLIuDSVRENq">said</a> that the firm expects expenses to climb to about $105 billion in 2026.Lake, during a Goldman Sachs conference last week, said that the second biggest driving factor of higher costs is the company’s strategic investments, which include building branches, adding bankers, adding advisors, investing in acquisition marketing, refreshing branches, investing in AI, in customer features and technology, and adding new products.Lake also said that investment banking revenue is expected to be up by the low-single digit percentages in the fourth quarter, and markets revenue to be up in the low-teens percentages.<h2 class="st-heading-2">Q3 Performance</h2>In October, JPM reported 9% growth in managed revenue to $47.1 billion driven by higher markets revenue and higher fees across asset management and investment banking, among others.The company also raised its net interest income forecast &nbsp;for the full year 2025 to $95.8 billion, up from its previous forecast of $95.5 billion. It expects interest income excluding markets of $95 billion in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around JPM stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/JPM">JPM stock</a> has gained nearly 34% this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/stocks-making-the-biggest-moves-today-december-15-2025/cLe4BltREoF">Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks Making The Biggest Moves Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a smartphone held in a hand displays the logo of JPMorgan Chase & Co.

JPMorgan Investment Banking Chief Plans Exit After 45 Years As Bank Ramps Up AI And Braces For $105B Costs: Report

According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking.

<ul class="summary-bullets"><li>Shield Technology Partners is a new IT Services platform backed by Thrive Holdings, a tech investment firm.</li><li>Jim Siders will be departing Palantir after 12 years at the company, most recently as its chief information officer.&nbsp;</li><li>Shield works with seven companies, mostly small and mid-sized businesses, and is expected to generate more than $100 million in revenue this year.</li></ul>Palantir Technologies Inc.’s (PLTR) Chief Information Officer, Jim Siders, will be leaving the company after 12 years to become the Chief Executive Officer at Shield Technology Partners.Shield Technology Partners is a new IT Services platform backed by Thrive Holdings, an investment firm with stakes in tech companies such as OpenAI, Stripe, and Databricks. Shield will partner with Thrive Holdings and OpenAI to integrate artificial intelligence into its partner businesses.According to a CNBC report, Thrive stated Shield is expected to generate more than $100 million in revenue this year and currently works with seven companies, primarily small and mid-sized businesses.“AI is rewriting the economics of service delivery at the exact time IT service providers are rethinking how they operate," stated Siders. “Shield is this incredible combination of long-term vision, technological expertise, and operational know-how that I think makes it perfect for this moment in time. We have lightning in a bottle.”<h2 class="st-heading-2">Journey At Palantir</h2>Jim Siders started his journey at Palantir as an IT helpdesk engineer and rose to chief information officer, overseeing global IT operations, infrastructure, and business applications in 2022.Siders oversaw Palantir at a time when the company’s revenue grew over $4 billion. He also led the setup of a federated structure that aligned technology and data workflows more directly with business value. Shares of <a href="https://stocktwits.com/symbol/PLTR">PLTR</a> are up over 147% in the past year.“Jim has been one of the early advocates for getting engineers to work directly alongside their customers,” said Anuj Mehndiratta, a member of the Thrive Holdings founding team. “He has been in the shoes of our partners and understands intuitively what their customers want.”Palantir has yet to make an official announcement of Siders’ departure. Meanwhile, the company has announced a three-year renewal of its contract with the DGSI, France's domestic intelligence agency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around PLTR remained ‘neutral’ over a week, and message volume stayed at ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1261/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_8_09_47_PM_png_5c84c88df3.webp" alt="On Stocktwits, the retail sentiment around PLTR remained ‘neutral’ over a week, and message volume stayed at ‘normal’ levels at the time of writing." width="1261" height="153"></figure>Shares of PLTR are up over 1.8% on Monday morning at the time of writing and have surged over 148% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

A computer with the acronym AI for Artificial Intelligence.

Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business

im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment. 

<ul class="summary-bullets"><li>The analyst expects the "death of software-as-a-service" will weigh down ServiceNow in 2026, according to TheFly.</li><li>Earlier, Bloomberg reported that ServiceNow is allegedly mulling the acquisition of a cybersecurity startup for $7 billion.</li><li>ServiceNow had posted market-beating results for its third quarter in October and also approved a five-for-one stock split.</li></ul>ServiceNow Inc. (NOW) shares traded over 5% lower in Monday’s pre-market after KeyBanc downgraded the stock.Analyst Jackson Ader at KeyBlanc downgraded <a href="https://stocktwits.com/symbol/NOW">NOW</a> to ‘Underweight’ from ‘Sector Weight’ with a price target of $775, according to TheFly. The back-office employment data suggest that the "death of software-as-a-service" narrative could start to weigh on ServiceNow in 2026, the analyst stated in a research note.<h2 class="st-heading-2">Acquisition Talks</h2>The downgrade comes on the back of a Bloomberg report stating that ServiceNow is looking to acquire Armis, a cybersecurity startup, in a $7 billion deal, which could be announced in the coming days.Earlier this month, the software-as-a-service (SaaS) company announced plans to acquire Veza, an identity security company, to augment its AI- and data-focused goals. “In the era of agentic AI, every identity — human, AI agent, or machine — is a force for enterprise impact. It’s only when you have continuous visibility into each identity’s permissions that you can trust it,” Amit Zavery, president, chief operating officer, and chief product officer at ServiceNow, said at the time.The Armis acquisition would further augment ServiceNow’s security capabilities. California-based Armis specializes in agentless cybersecurity that helps identify and track security threats on devices across industries.ServiceNow posted market-beating results for its third quarter in October and also approved a five-for-one stock split. Earlier this month, Dan Ives, managing director at Wedbush Securities, also <a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-updates-ai-30-winner-list-ahead-of-2026-sound-hound-service-now-salesforce-removed/cLI7XbjREiS">announced</a> that ServiceNow Inc. (NOW) had been removed from the IVES AI 30 winner list.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, ServiceNow was trending in the seventh position on Monday morning. The retail sentiment around NOW jumped to ‘bullish’ from ‘neutral’ territory a day ago, while message volume increased to ‘high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1268/133;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_6_26_59_PM_png_0aa34524b3.webp" alt="The retail sentiment around NOW jumped to ‘bullish’ from ‘neutral’ territory a day ago, while message volume increased to ‘high’ from ‘normal’ levels at the time of writing." width="1268" height="133"></figure>Shares of NOW are down over 23% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the logo of ServiceNow, Inc. is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China.

ServiceNow Stock Is Down 5% Today — What’s Weighing On The Shares?

KeyBank downgraded ServiceNow to ‘Underweight’ from ‘Sector Weight’ with a price target of $775. 

ServiceNow Stock Is Down 5% Today – What’s Weighing On The Shares?

<ul class="summary-bullets"><li>The company reported Q4 adjusted earnings per share of $1.95, above a Wall Street estimate of $1.87, according to data from Fiscal AI.&nbsp;</li><li>The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion.&nbsp;</li><li>Broadcom, like Nvidia, has greatly benefited from the AI boom with its abilities in designing custom AI chips.</li></ul> Shares of Broadcom Inc (AVGO) rose 2.3% after hours on Thursday after the company reported fourth quarter (Q4) earnings that beat Wall Street expectations and issued an upbeat outlook for the first quarter of 2026.The company reported Q4 adjusted earnings per share of $1.95, above a Wall Street estimate of $1.87, according to data from Fiscal AI.Revenue for the three months came in at $18.02 billion, marking a growth of 28% year-over-year, and above an analyst estimate of $17.46 billion.<h2 class="st-heading-2">Q1 2026 Forecast</h2>The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion, on the back of strong AI chip and semiconductor demand."We see the momentum continuing in Q1 and expect AI semiconductor revenue to double year-over-year to $8.2 billion, driven by custom AI accelerators and Ethernet AI switches,” CEO Hock Tan said in a statement. The company further expects first quarter core profit to be 67% of projected revenue.However, in the non-AI semiconductor segment, the company expects revenue to be about $4.1 billion in the quarter, flat from a year ago. “Directionally, we expect AI revenue to continue to accelerate and drive most of our growth, and non-AI semiconductor revenue to be stable,” the CEO said.<h2 class="st-heading-2">AI Boom Aids Stock Rally</h2>Broadcom, like Nvidia, has greatly benefited from the AI boom with its abilities in designing custom AI chips. AVGO stock has gained over 75% this year and by about 122% over the past 12 months.Tan said on Thursday that the company now has about $73 billion in AI backlog, almost half of the company’s consolidated backlog of $162 billion. The company expects to deliver the AI backlog over the next 18 months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVGO">AVGO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user sounded optimistic about the stock hitting $500 in Friday trading.<stembedurl>https://stocktwits.com/buyacramer/message/638934302</stembedurl>Another sounded hopes for a Microsoft partnership.<stembedurl>https://stocktwits.com/bestest1/message/638934125</stembedurl>The company inked a partnership with OpenAI in October to develop custom chips.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/costco-stock-dips-after-hours-despite-strong-q1-holiday-momentum/cLIxATXREF4">Costco Stock Dips After Hours Despite Strong Q1 And Holiday Momentum — Retail Bulls Eye Rally Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The Broadcom Ink logo is displayed on a mobile phone in this photo illustration in Brussels, Belgium, on September 2, 2025. 

Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook

The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand. 

<ul class="summary-bullets"><li>The company said that reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at month 3 and month 6 in the trial.</li><li>The company said that the results are supportive of a late-stage registrational trial.&nbsp;</li><li>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares.</li></ul>Shares of Rhythm Pharmaceuticals, Inc. (RYTM) jumped 14% on Thursday after the company announced that its mid-stage study evaluating Setmelanotide in Prader-Willi Syndrome patients showed reduction in weight and hyperphagia.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-preliminary-data-exploratory">said</a> that the reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at the third and sixth-month mark in the trial. The company said that the results are supportive of a late-stage registrational trial.<h2 class="st-heading-2">Trial Design</h2>The company enrolled 18 patients with Prader-Willi Syndrome (PWS) in the ongoing 52 week trial. Of this, 17 patients remain enrolled on active Setmelanotide therapy and the company will share additional data in the first half of 2026, it added.PWS is a rare genetic disorder requiring lifelong management and causing poor muscle tone and feeding issues in infancy, followed by relentless hunger (hyperphagia) and severe obesity in childhood, alongside developmental delays, learning disabilities, and distinctive behavioral problems. PWS is estimated to affect approximately 400,000 people worldwide and approximately 20,000 people in the United States, as per Rhythm.The company said that safety and tolerability profile of Setmelanotide therapy in the trial was consistent with the drug’s established clinical profile. In the United States, Setmelanotide is already indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to certain conditions including Bardet-Biedl syndrome.Rhythm is also looking to evaluate its experimental therapy RM-718 in PWS and expects the first patient with PWS to enter screening for this study in December.<h2 class="st-heading-2">Expert Take</h2>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares. The firm, which is "encouraged" by the preliminary update, argues that a successful late-stage study in PWS would "offer an attractive commercial opportunity."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/59;" src="data:image/png;base64,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" width="586" height="59" alt="RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits"><figcaption>RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RYTM">RYTM stock</a> has more than doubled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apollo-global-management-weighs-ipo-or-sale-of-invited-in-potential-deal-that-could-top-3-billion/cLIxS8NREnC">Apollo Global Management Weighs IPO Or Sale Of Invited In Potential Deal That Could Top $3B: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder 

 The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

VFMO
Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VFMO News

VFMOVanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF